<DOC>
	<DOC>NCT00410072</DOC>
	<brief_summary>The purpose of this study is to compare the effectiveness of entecavir plus tenofovir combination therapy with that of entecavir monotherapy. Safety will also be studied.</brief_summary>
	<brief_title>Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Chronic hepatitis B virus (HBV) infection (hepatitis B e antigen [HbeAg]positive or negative) disease Nucleoside and nucleotidenaive Males or females ≥16 years of age (or minimum age of consent in a given country) Compensated liver function HBV DNA &gt;1.72*10*5*IU/mL (approximately 10*6*copies/mL) for HbeAgpositive participants HBV DNA &gt;1.72*10*4*IU/mL (approximately 10*5*copies/mL) for HbeAgnegative participants Alanine aminotransferase level ≥*upper limit of normal (ULN) and ≤10*ULN Evidence of decompensated cirrhosis Coinfection with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus Laboratory values out of protocolspecified range</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>